Ligand Pharmaceuticals (NASDAQ:LGND) inks an agreement with Pandion Therapeutics granting the latter a non-exclusive global license to its OmniAb antibody discovery platform.
Under the terms of the deal, Ligand will receive an upfront fee, milestones and royalties on net sales. Specific financial terms remain confidential.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.